[go: up one dir, main page]

MX2010002448A - Formulacion liquida del g-csf conjugado. - Google Patents

Formulacion liquida del g-csf conjugado.

Info

Publication number
MX2010002448A
MX2010002448A MX2010002448A MX2010002448A MX2010002448A MX 2010002448 A MX2010002448 A MX 2010002448A MX 2010002448 A MX2010002448 A MX 2010002448A MX 2010002448 A MX2010002448 A MX 2010002448A MX 2010002448 A MX2010002448 A MX 2010002448A
Authority
MX
Mexico
Prior art keywords
composition
salts
stimulating factor
colony stimulating
granulocyte colony
Prior art date
Application number
MX2010002448A
Other languages
English (en)
Inventor
Walter Hinderer
Christian Scheckermann
Original Assignee
Biogenerix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenerix Ag filed Critical Biogenerix Ag
Publication of MX2010002448A publication Critical patent/MX2010002448A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica líquida que comprende un polipéptido del factor estimulador de colonias de granulocitos conjugado con un polímero, la composición tiene un valor de pH en la variación de 4.5 a 5.5. La composición comprende además un tensioactivo y opcionalmente uno o más de otros excipientes farmacéuticamente aceptables. Además, la composición de la invención está libre de ácido tartárico o las sales del mismo y de ácido succínico o. las sales del mismo como agentes amortiguadores y no contiene aminoácidos como estabilizante. La composición tiene una buena estabilidad en almacenamiento y es especialmente útil para la profilaxis y tratamiento de trastornos e indicaciones médicas donde se consideran como remedios útiles las preparaciones del factor estimulador de colonias de granulocitos.
MX2010002448A 2007-08-27 2008-08-27 Formulacion liquida del g-csf conjugado. MX2010002448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115047 2007-08-27
PCT/EP2008/061232 WO2009027437A1 (en) 2007-08-27 2008-08-27 Liquid formulation of g-csf conjugate

Publications (1)

Publication Number Publication Date
MX2010002448A true MX2010002448A (es) 2010-10-04

Family

ID=39862881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002448A MX2010002448A (es) 2007-08-27 2008-08-27 Formulacion liquida del g-csf conjugado.

Country Status (24)

Country Link
US (1) US8546328B2 (es)
EP (2) EP2578235A3 (es)
JP (2) JP5570988B2 (es)
KR (1) KR20100052501A (es)
CN (2) CN101827864A (es)
AU (1) AU2008292186B9 (es)
BR (1) BRPI0815975B8 (es)
CA (1) CA2696594C (es)
CY (1) CY1115908T1 (es)
DE (1) DE202008017456U1 (es)
DK (1) DK2197919T3 (es)
EA (1) EA020069B1 (es)
ES (1) ES2476915T3 (es)
HR (1) HRP20140590T1 (es)
IL (1) IL204190A (es)
MX (1) MX2010002448A (es)
NZ (1) NZ583276A (es)
PL (1) PL2197919T3 (es)
PT (1) PT2197919E (es)
RS (1) RS53404B (es)
SI (1) SI2197919T1 (es)
UA (1) UA98001C2 (es)
WO (1) WO2009027437A1 (es)
ZA (1) ZA201000798B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867777B2 (en) * 2010-01-19 2018-01-16 Hanmi Science Co., Ltd. Liquid formulations for long-acting G-CSF conjugate
KR101853146B1 (ko) 2010-03-17 2018-04-27 라티오팜 게엠베하 생물학적으로 활성인 재조합 인간 ｇ­ｃｓｆ의 수득 방법
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
TWI751154B (zh) * 2016-04-18 2022-01-01 大陸商江蘇恆瑞醫藥股份有限公司 一種重組人粒細胞集落刺激因子的製備方法
IT201700108526A1 (it) * 2017-09-28 2019-03-28 Alfasigma Spa Composizioni orali per il trattamento del refluso gastroesofageo.
KR102589578B1 (ko) * 2018-05-04 2023-10-17 일코겐 일라익 사나이 비 티카렛 에이.에스. 안정한 하이브리드 fc 융합 g-csf 제형
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
CN114224853B (zh) * 2022-01-04 2022-09-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂
CN119698274A (zh) * 2022-08-19 2025-03-25 亿一生物医药开发(上海)有限公司 包含g-csf的制剂及其用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (es) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US5675941A (en) 1983-12-09 1997-10-14 Dykmans; Maximiliaan J. Method and apparatus for constructing prestressed structures utilizing a membrane and floating dome assembly
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
KR0133561B1 (ko) 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
AU677789B2 (en) 1992-07-02 1997-05-08 Collagen Corporation Biocompatible polymer conjugates
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
DE69534676T2 (de) 1994-02-08 2006-08-17 Amgen Inc., Thousand Oaks Orale Verabreichung von chemisch modifizierten Proteinen
CA2183871C (en) 1994-02-23 2008-11-04 Motoo Yamasaki Platelet growth accelerator
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CN1273589C (zh) 1996-02-15 2006-09-06 诺沃奇梅兹有限公司 多肽缀合
CA2278178C (en) 1997-01-16 2012-09-25 Cytel Corporation Practical in vitro sialylation of recombinant glycoproteins
CN1250566C (zh) 1997-06-06 2006-04-12 协和发酵工业株式会社 化学修饰的多肽
US6540672B1 (en) * 1998-12-09 2003-04-01 Novo Nordisk A/S Medical system and a method of controlling the system for use by a patient for medical self treatment
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP1260230A4 (en) 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd LONG-TERM STABILIZED PREPARATIONS
MXPA02011016A (es) 2000-05-12 2004-03-16 Neose Technologies Inc Glicopeptidos recombinantes de glucolisacion in vitro.
CZ304855B6 (cs) 2000-05-15 2014-12-10 F. Hoffmann-La Roche Ag Kapalná farmaceutická kompozice obsahující pegylovaný lidský erythropoetin, způsob její přípravy, léčivo pro léčení chorob korelujících s anemií při chronickém renálním selhání a zařízení s jejím obsahem
ES2290142T3 (es) 2000-05-16 2008-02-16 Bolder Biotechnology, Inc. Metodos para replegamiento de proteinas que contiene residuos de cisteina libre.
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
AU8260701A (en) * 2000-09-01 2002-03-13 Chugai Pharmaceutical Co Ltd Solution preparations stabilized over long time
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
DK2279755T3 (da) 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
SI21273A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
PL1660134T3 (pl) 2003-08-08 2011-05-31 Fresenius Kabi Deutschland Gmbh Koniugaty hydroksyalkiloskrobi i G-CSF
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
US7585496B2 (en) 2003-11-04 2009-09-08 Lek Pharmaceuticals D.D. Stable pharmaceutical composition granulocyte-colony stimulating factor
KR101237884B1 (ko) 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
JP5743368B2 (ja) * 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
EP1725589A1 (en) 2004-03-11 2006-11-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
CN1929865B (zh) 2004-03-11 2011-11-16 费森尤斯卡比德国有限公司 羟烷基淀粉和蛋白质的接合物
DE102004036909B4 (de) 2004-07-29 2007-04-05 Infineon Technologies Ag Halbleiterbasisbauteil mit Verdrahtungssubstrat und Zwischenverdrahtungsplatte für einen Halbleiterbauteilstapel sowie Verfahren zu deren Herstellung
EP2514757A3 (en) * 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
EP1869078A2 (en) 2005-03-17 2007-12-26 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
BRPI0611221A2 (pt) 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate

Also Published As

Publication number Publication date
EP2197919B1 (en) 2014-04-09
CN101827864A (zh) 2010-09-08
JP2014101362A (ja) 2014-06-05
EP2578235A3 (en) 2013-08-28
NZ583276A (en) 2012-06-29
ZA201000798B (en) 2010-10-27
CA2696594A1 (en) 2009-03-05
IL204190A (en) 2015-01-29
AU2008292186B9 (en) 2014-07-03
WO2009027437A1 (en) 2009-03-05
CN104689333A (zh) 2015-06-10
JP2010536929A (ja) 2010-12-02
JP5570988B2 (ja) 2014-08-13
DE202008017456U1 (de) 2009-08-27
ES2476915T3 (es) 2014-07-15
CN104689333B (zh) 2018-05-29
AU2008292186A1 (en) 2009-03-05
BRPI0815975B8 (pt) 2021-05-25
US8546328B2 (en) 2013-10-01
PL2197919T3 (pl) 2014-09-30
UA98001C2 (uk) 2012-04-10
JP5836351B2 (ja) 2015-12-24
DK2197919T3 (da) 2014-07-07
EA201070315A1 (ru) 2010-08-30
CA2696594C (en) 2019-03-19
AU2008292186B2 (en) 2014-02-27
RS53404B (sr) 2014-10-31
EP2578235A2 (en) 2013-04-10
EP2197919A1 (en) 2010-06-23
PT2197919E (pt) 2014-07-17
CY1115908T1 (el) 2017-01-25
HRP20140590T1 (hr) 2014-08-15
US20110053844A1 (en) 2011-03-03
BRPI0815975B1 (pt) 2019-04-02
EA020069B1 (ru) 2014-08-29
KR20100052501A (ko) 2010-05-19
BRPI0815975A2 (pt) 2015-02-18
SI2197919T1 (sl) 2014-09-30

Similar Documents

Publication Publication Date Title
MX2010002448A (es) Formulacion liquida del g-csf conjugado.
MX2010008802A (es) Formulacion liquida de la fsh.
CN111295202B (zh) 治疗甲癣的外用制剂
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2007113687A3 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
WO2000068229A3 (en) (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
KR20190075956A (ko) 에피나스틴 함유 점안액
MXPA02000849A (es) Composicion oftalmica que comprende cetotifeno.
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same
JO3008B1 (ar) تركيب صيدلي لتخفيف الألم
JPH115744A (ja) ヒアルロン酸含有の外用水溶液製剤
WO2006054315B1 (en) Nonaqueous liquid parenteral aceclofenac formulation
PH12022551043A1 (en) Combination of a cxcr7 antagonist with an s1p1 receptor modulator
JP2012062269A (ja) 角膜上皮障害治療用点眼剤
JP2002020320A (ja) 点眼液用防腐剤
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
JP2012036167A (ja) 内服液剤
JP5565995B2 (ja) 鎮痒剤
WO2025028651A1 (ja) 爪白癬用外用剤
JP5887893B2 (ja) 内服液剤
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria
JP2011074033A (ja) 外用医薬組成物